Drugs / BIIB113
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05195008 | Jan 2022 → Jul 2023 | — | Biogen | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIIB113 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05195008 ↗ |
| Action | Inhibit | “BIIB113 is a small molecule inhibitor of OGA” NCT05195008 ↗ |
| Modality | Small molecule | “BIIB113 is a small molecule inhibitor of OGA” NCT05195008 ↗ |
| Route | Oral | “single and multiple ascending oral doses of BIIB113” NCT05195008 ↗ |
| Target | OGA | “BIIB113 is a small molecule inhibitor of OGA” NCT05195008 ↗ |